RNS Number: 3275G EKF Diagnostics Holdings PLC

28 April 2025

## **EKF Diagnostics Holdings plc**

("EKF" or the "Company")

# Posting of Annual Report & Accounts and Notice of AGM

EKF Diagnostics Holdings plc(AIM: EKF), the AIM-listed global diagnostics business, confirms that the Annual Report and Accounts for the year ended 31 December 2024 ("2024 Annual Report") which includes the Notice of the 2025 Annual General Meeting ("AGM") have now been published on the Company's website via:

#### https://www.ekfdiagnostics.com/documents-reports.html

The 2024 Annual Report, the Notice of AGM and details for voting by proxy have been posted today to shareholders who have requested hard copies.

The AGM is to be held at 11:00 am on 20 May 2025 at Harwood Capital LLP, 6 Stratton Street Mayfair, London W1J 8LD and will consider the Resolutions set out in the Notice of AGM.

The Company is providing a facility for shareholders to listen in to the AGM either online or telephonically (in a non-voting capacity) and there will be an opportunity for shareholders to ask questions. In order to facilitate the process, the Directors would request that shareholders register for the meeting and submit questions in advance, before 11:00 am on Friday, 16 May 2025. To register for dial-in details and to submit any questions please contact Walbrook PR via email at <a href="mailto:ekf@walbrookpr.com">ekf@walbrookpr.com</a> or call +44 (0)20 7933 8780.

### **Proxy voting**

EKF Diagnostics Holdings plc is not sending out a Form of Proxy this year with this Notice of Annual General Meeting.

Shareholders are being encouraged to vote online via the Investor Centre app or by logging on to <a href="https://uk.investorcentre.mpms.mufg.com/">https://uk.investorcentre.mpms.mufg.com/</a> and following the instructions given.

Shareholders can request a hard copy proxy directly from the Registrars, MUFG Corporate Markets at <a href="mailto:shareholderenquiries@cm.mpms.mufg.com">shareholderenquiries@cm.mpms.mufg.com</a> or on Tel: 0371 664 0391. Calls are charged at the standard geographic rate and will vary by provider. Calls outside the United Kingdom will be charged at the applicable international rate. Lines are open between 09:00 - 17:30, Monday to Friday excluding public holidays in England and Wales.

**EKF Diagnostics Holdings plc** 

Julian Baines, Executive Chair / Stephen Young, CFO

www.ekfdiagnostics.com via Walbrook PR

Tel: +44 (0)20 7496 3000

Singer Capital Markets (Nominated Adviser & Broker)

Phil Davies / Oliver Platts

Tel: +44 (0)20 7933 8780 or <a href="mailto:ekf@walbrookpr.com">ekf@walbrookpr.com</a>
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

Walbrook PR Limited

Paul McManus / Alice Woodings



## About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

EKF is an AIM-listed global diagnostics business focussed on:

- Point-of-Care analysers in the key areas of Hematology and Diabetes
- Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact <a href="mailto:msc.dec.">msc.dec.</a> www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

**END** 

NOAUBAORVVUSUAR